A284620 Stock Overview
Researches and develops various medicines for cancers, brain, and infectious diseases in South Korea and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Kainos Medicine, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩2,770.00 |
| 52 Week High | ₩7,100.00 |
| 52 Week Low | ₩2,275.00 |
| Beta | 0 |
| 11 Month Change | -48.51% |
| 3 Month Change | -33.57% |
| 1 Year Change | -23.06% |
| 33 Year Change | -78.57% |
| 5 Year Change | n/a |
| Change since IPO | -86.89% |
Recent News & Updates
Recent updates
Shareholder Returns
| A284620 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -24.2% | -1.5% | 0.9% |
| 1Y | -23.1% | 23.1% | -3.4% |
Return vs Industry: A284620 underperformed the KR Biotechs industry which returned 23.1% over the past year.
Return vs Market: A284620 underperformed the KR Market which returned -3.4% over the past year.
Price Volatility
| A284620 volatility | |
|---|---|
| A284620 Average Weekly Movement | 12.2% |
| Biotechs Industry Average Movement | 8.1% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in KR Market | 11.6% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A284620's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A284620's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | n/a | Ki-Sub Lee | www.kainosmedicine.com |
Kainos Medicine, Inc. researches and develops various medicines for cancers, brain, and infectious diseases in South Korea and internationally. The company’s product pipeline includes KM-819, which is completed Phase I clinical study for the treatment of Parkinson’s disease; and KM023, a novel non-nucleoside reverse transcriptase inhibitor that is in Phase III clinical study to treat HIV/AIDS. It is also developing anticancer agents, including DNA methyltransferase inhibitor; gene target anti-cancer agent; and Ara-C, a cytotoxic anti-cancer agent to treat acute myeloid leukemia, as well as small molecule immuno-oncology drugs that modulate anti-cancer abilities of immune cells.
Kainos Medicine, Inc. Fundamentals Summary
| A284620 fundamental statistics | |
|---|---|
| Market cap | ₩78.34b |
| Earnings (TTM) | ₩39.92m |
| Revenue (TTM) | n/a |
0.0x
P/E Ratio0.0x
P/S RatioIs A284620 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A284620 income statement (TTM) | |
|---|---|
| Revenue | ₩0 |
| Cost of Revenue | ₩0 |
| Gross Profit | ₩0 |
| Other Expenses | -₩39.92m |
| Earnings | ₩39.92m |
Last Reported Earnings
Mar 31, 2020
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did A284620 perform over the long term?
See historical performance and comparison